Medline Inc. logo

Medline Inc.

MDLN

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$34.26

+$1.68 · +5.16%

Aug 21, 4:00 PM ET

MDLN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

76

Undervalued

Momentum

41

Neutral

Sentiment

49

Mixed

Risk resilience

62

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings. Offerings range from surgical procedure trays, drapes, and gowns to personal protective equipment (PPE), sterile wraps, various surgical instruments, specialized surgeon's gloves, complete procedure kits, and orthopedic implants. Finally, Laboratory and Diagnostics supplies critical solutions for clinical testing and analysis. This includes point-of-care testing devices, analytical instruments, laboratory consumables, advanced diagnostic equipment, vital signs monitoring systems, and products for anatomic pathology and phlebotomy. The Supply Chain Solutions segment is responsible for sourcing and distributing a diverse portfolio of third-party products, including those from well-known national brands. Beyond distribution, this segment offers comprehensive logistics and supply chain optimization services to clients both domestically and internationally. These optimization services encompass strategic consulting, outsourced management of warehousing and technology, specialized "put-away-ready" packaging, third-party logistics (3PL), inventory rationalization strategies, and efficient route planning. Established in 1966, Medline Inc. maintains its headquarters in Northfield, Illinois.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
James Boyle
Listed since
Dec 17, 2025
Employees
45,000

Market position

Day range

Current $34.26

52-week range

Current $34.26

Open
$32.51
Previous close
$32.58
Volume
6.99M
0.79× average
Average volume
8.8M
Average daily volume
Market cap
28.97B USD
Beta
-0.41
Market reference 1
50-day average
$37.9855
-9.81% below average
200-day average
$41.3586
-17.16% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
39.84×
P/B (TTM)
2.54×
P/S (TTM)
0.97×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
25.02%
Operating margin
6.07%
Net margin
2.31%

Financial health

Debt / equity
1.09×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends29%18%8%-3%Gross margin, FY2022: 21.25%Gross margin, FY2023: 22.48%Gross margin, FY2024: 24.66%Gross margin, FY2025: 26.44%Operating margin, FY2022: 4.06%Operating margin, FY2023: 6.22%Operating margin, FY2024: 8.72%Operating margin, FY2025: 7.78%Net margin, FY2022: -0.12%Net margin, FY2023: 1.01%Net margin, FY2024: 4.70%Net margin, FY2025: 4.08%FY2022FY2023FY2024FY2025
Gross margin FY2022 21.25%. Gross margin FY2023 22.48%. Gross margin FY2024 24.66%. Gross margin FY2025 26.44%. Operating margin FY2022 4.06%. Operating margin FY2023 6.22%. Operating margin FY2024 8.72%. Operating margin FY2025 7.78%. Net margin FY2022 -0.12%. Net margin FY2023 1.01%. Net margin FY2024 4.70%. Net margin FY2025 4.08%.

Income trends

Revenue

28.43B USD+11.47%

Operating income

2.21B USD-0.58%

Net income

1.16B USD-3.42%
Income trends across reported periods31.28B USD19.89B USD8.51B USD−2.87B USDRevenue, FY2022: 21.45B USDRevenue, FY2023: 23.23B USDRevenue, FY2024: 25.51B USDRevenue, FY2025: 28.43B USDOperating income, FY2022: 870M USDOperating income, FY2023: 1.44B USDOperating income, FY2024: 2.23B USDOperating income, FY2025: 2.21B USDNet income, FY2022: −25M USDNet income, FY2023: 234M USDNet income, FY2024: 1.2B USDNet income, FY2025: 1.16B USDFY2022FY2023FY2024FY2025
Revenue FY2022 21.45B USD. Revenue FY2023 23.23B USD. Revenue FY2024 25.51B USD. Revenue FY2025 28.43B USD. Operating income FY2022 870M USD. Operating income FY2023 1.44B USD. Operating income FY2024 2.23B USD. Operating income FY2025 2.21B USD. Net income FY2022 −25M USD. Net income FY2023 234M USD. Net income FY2024 1.2B USD. Net income FY2025 1.16B USD.
Metric (USD)FY2025FY2024FY2023FY2022
Revenue28.43B USD25.51B USD23.23B USD21.45B USD
Cost of goods sold20.91B USD19.22B USD18.01B USD16.89B USD
Gross profit7.52B USD6.29B USD5.22B USD4.56B USD
Research and development67M USD60M USD58M USD
Selling, general, and administrative4.52B USD4.04B USD3.81B USD3.62B USD
Operating expenses5.31B USD4.07B USD3.78B USD3.69B USD
Interest income280M USD237M USD27M USD
Interest expense812M USD1.31B USD1.38B USD911M USD
Depreciation and amortization704M USD977M USD951M USD933M USD
Operating income2.21B USD2.23B USD1.44B USD870M USD
Net income1.16B USD1.2B USD234M USD−25M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
2 beats, 1 miss, 0 met estimates
Average EPS surprise
+16.01%
3 comparable reports
Latest EPS result
0.5
Estimate 0.35 · Beat by 41.88%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.540.420.310.19Q4 '25No estimateQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q4 2025, reported Nov 4, 2025: actual 0.31, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual 0.225, estimate 0.238, surprise -5.63%, Miss. Q2 2026, reported May 6, 2026: actual 0.33, estimate 0.295, surprise +11.79%, Beat. Q3 2026, reported Aug 5, 2026: actual 0.5, estimate 0.352, surprise +41.88%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.34, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates8.1B7.67B7.24B6.8BQ4 '25No estimateQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q4 2025, reported Nov 4, 2025: actual 7.12B USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual 7.79B USD, estimate 7.51B USD, surprise +3.66%, Beat. Q2 2026, reported May 6, 2026: actual 7.35B USD, estimate 7.16B USD, surprise +2.64%, Beat. Q3 2026, reported Aug 5, 2026: actual 7.69B USD, estimate 7.52B USD, surprise +2.21%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 7.72B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$46.33

35.23% upside
Past 12 months12-month forecastHigh $60.00Average $46.33Low $37.00

MDLN news

MDLN peers

ETFs holding MDLN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research MDLN

research.disclaimer